Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up
Anna M. Wagner, Sara A. Bonderoff, Stanley Chang, Jeffrey Deignan, Michelle M. Esanu, Huy V. Huynh, Tianmin Niu, Vinh Ngo, B. Michael O’Keefe, Jenny Phoenix, Trevor J. Rainey, Benjamin Roberts, Jinyu Shen, Craig R. Stewart, Amanda L. Vandehey, Scott A. Wolckenhauer, Chloe Y. Wong, Brian H. Yarmuch
Abstract
Lenacapavir sodium (GS-6207-02) is a first-in-class HIV capsid inhibitor. Process development of the four-step final assembly of lenacapavir sodium from four synthetic intermediates is described here. A bis-bromopyridine core is sequentially subjected to an alkynylation, an amide coupling with a chiral pyrazole carboxylic acid, and a Suzuki cross-coupling with an indazole boronic ester. The final step is a telescoped bis-methanesulfonylation and hydrolysis to yield the API. This report highlights experimental work on the final assembly sequence to establish robust processing conditions, minimize process mass intensity, control impurity formation, understand impurity purge, and enable large-scale manufacturing of lenacapavir sodium.